Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells
Journal article
Athanasiadis P. et al, (2023), iScience, 26
-
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Journal article
Buckell J. et al, (2023), Sci Rep, 13
-
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Journal article
Wei J. et al, (2023), Nat Commun, 14
-
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.
Journal article
Emmenegger M. et al, (2023), iScience
-
Longitudinal characterization of TK6 cells sequentially adapted to animal product-free, chemically defined culture medium: considerations for genotoxicity studies.
Journal article
Perez-Diaz N. et al, (2023), Front Toxicol, 5